Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non‐Hodgkin lymphoma

Abstract

Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy worldwide, which encompasses three broad molecule categories including B-cell, T-cell, and natural killer (NK)-cell neoplasms. 1 Clinical manifestation and pathological features are highly heterogeneous across NHL subtypes, varying from the most indolent to the most aggressive malignancies. 2 It is known that etiologic heterogeneity of NHLs is associated with diverse risk factors and molecular mechanisms such as genomic alterations. 2,3 Targeted next-generation sequencing (NGS) has been recently utilized to uncover mutation features of NHLs. 4 A better

The Novel Prognostic Index Model of Combining Circulating Tumor DNA and PINK-E Predicts the Clinical Outcomes for Newly Diagnosed Extranodal NK/T-cell Lymphoma

“…Some studies have reported that monitoring ctDNA can reflect treatment response, monitor disease progression, and facilitate prediction of prognosis in some solid cancers 39,41–43 . Recently, some research reported that ctDNA had prognostic value in lymphoma patients 25,27,44 . Our previous work had demonstrated that ctDNA assessment could predict the therapy response and monitor disease status in a noninvasive way in ENKTL 28 .…”

“…39,[41][42][43] Recently, some research reported that ctDNA had prognostic value in lymphoma patients. 25,27,44 Our previous work had demonstrated that ctDNA assessment could predict the therapy response and monitor disease status in a noninvasive way in ENKTL. 28 The plasma ctDNA concentration was significantly correlated with the MTV.…”

“…Fu et al generated models for predicting OS or progression-free survival (PFS) using ctDNA together with the IPI, which had a better accuracy of prognostic prediction. 27 Our previous work demonstrated that the plasma ctDNA was feasible, and we also unveiled the mutation spectrum of ENKTL patients and found that the concentration of ctDNA was positively correlated with tumor stage and tumor burden, but the prognostic significance of ctDNA was not fully elucidated. 28 In this study, we analyzed the specific prognostic significance of ctDNA, and we also developed a novel prognostic index model incorporating ctDNA into PINK-E (PINK-EC) for the estimation of clinical prognosis in ENKTL.…”

“…Alig et al 26 demonstrated that pretreatment ctDNA levels predicted a shorter diagnosis‐to‐treatment interval (DTI) independent of the IPI score. Fu et al generated models for predicting OS or progression‐free survival (PFS) using ctDNA together with the IPI, which had a better accuracy of prognostic prediction 27 . Our previous work demonstrated that the plasma ctDNA was feasible, and we also unveiled the mutation spectrum of ENKTL patients and found that the concentration of ctDNA was positively correlated with tumor stage and tumor burden, but the prognostic significance of ctDNA was not fully elucidated 28 .…”

Genetic Profiling of Cell-Free DNA in Liquid Biopsies: A Complementary Tool for the Diagnosis of B-Cell Lymphomas and the Surveillance of Measurable Residual Disease

“…Mature B-cell neoplasms comprise more than 80% of non-Hodgkin lymphomas and consist of different pathological subtypes with variable clinical outcomes [ 1 ]. Tumor tissue biopsies are the gold standard to analyze lymphoma genetic profiles, identifying useful mutations as molecular biomarkers [ 2 , 3 ]. Moreover, targeted next-generation sequencing (NGS) has contributed to reclassifying molecular subtypes of lymphomas through new algorithmic models.…”